Phase Ib Study of ABBV-744, a Novel, Selective BET Inhibitor, As Monotherapy for Patients with Myelofibrosis

Scientists reported the outcomes of a multicenter, open-label Phase Ib study of ABBV-744 in patients with myelofibrosis who received ≥1 previous lines of therapy, including a Janus kinase inhibitors.